Quantitative proteomics analysis of COVID-19 patients: Fetuin-A and tetranectin as potential modulators of innate immune responses.
COVID-19
Fetuin-A
Innate immunity
Mass spectrometry
Proteomics
Tetranectin
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
03
01
2023
revised:
26
03
2023
accepted:
30
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
ppublish
Résumé
Treatment of severe cases of coronavirus disease 2019 (COVID-19) is extremely important to minimize death and end-organ damage. Here we performed a proteomic analysis of plasma samples from mild, moderate and severe COVID-19 patients. Analysis revealed differentially expressed proteins and different therapeutic potential targets related to innate immune responses such as fetuin-A, tetranectin (TN) and paraoxonase-1 (PON1). Furthermore, protein changes in plasma showed dysregulation of complement and coagulation cascades in COVID-19 patients compared to healthy controls. In conclusion, our proteomics data suggested fetuin-A and TN as potential targets that might be used for diagnosis as well as signatures for a better understanding of the pathogenesis of COVID-19 disease.
Identifiants
pubmed: 37064481
doi: 10.1016/j.heliyon.2023.e15224
pii: S2405-8440(23)02431-3
pmc: PMC10082967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15224Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Front Immunol. 2021 Sep 20;12:728896
pubmed: 34616396
Sci Rep. 2020 Nov 25;10(1):20560
pubmed: 33239692
Cell. 2021 Feb 4;184(3):775-791.e14
pubmed: 33503446
Eur J Cancer. 2021 May;149:102-104
pubmed: 33848711
Cell. 2022 Feb 3;185(3):493-512.e25
pubmed: 35032429
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2232
pubmed: 32451547
Lancet. 1997 Sep 20;350(9081):861-2
pubmed: 9310607
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
Exp Biol Med (Maywood). 2021 Jun;246(11):1307-1317
pubmed: 33653159
Front Immunol. 2020 Mar 20;11:484
pubmed: 32265930
Sci Adv. 2022 Aug 5;8(31):eabp9770
pubmed: 35921414
Cell Commun Signal. 2019 Sep 2;17(1):113
pubmed: 31477130
Genomics. 2021 Jul;113(4):1733-1741
pubmed: 33838280
Clin Sci (Lond). 2003 Sep;105(3):273-8
pubmed: 12725640
FASEB J. 2021 Sep;35(9):e21801
pubmed: 34365657
JBMR Plus. 2020 Dec 03;5(2):e10429
pubmed: 33615102
Cardiovasc Res. 2022 Jul 20;118(9):2179-2195
pubmed: 34375400
Nephron Clin Pract. 2008;108(3):c233-40
pubmed: 18334823
Cell Rep Methods. 2022 Sep 19;2(9):100279
pubmed: 35975199
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Signal Transduct Target Ther. 2021 Apr 15;6(1):155
pubmed: 33859163
Chem Soc Rev. 2012 May 21;41(10):3912-28
pubmed: 22498958
Nature. 2022 Mar;603(7902):587-598
pubmed: 35090163
Nat Rev Immunol. 2014 Mar;14(3):166-80
pubmed: 24481336
J Immunol. 2012 Jun 1;188(11):5682-93
pubmed: 22523386
Curr Mol Med. 2012 Jun;12(5):625-33
pubmed: 22292896
J Pharm Biomed Anal. 2022 Aug 5;217:114827
pubmed: 35569273
J Infect. 2022 Nov;85(5):e152-e154
pubmed: 35940349
Front Immunol. 2021 Dec 24;12:760770
pubmed: 35003072
Front Immunol. 2021 Sep 08;12:730710
pubmed: 34566994
Nat Commun. 2021 Jan 22;12(1):549
pubmed: 33483479
Biomolecules. 2022 Jun 02;12(6):
pubmed: 35740904
Crit Care. 2021 Jun 30;25(1):224
pubmed: 34193220
Cells. 2021 Aug 27;10(9):
pubmed: 34571869
Cell Death Dis. 2022 Mar 14;13(3):235
pubmed: 35288537
Atherosclerosis. 2013 Jun;228(2):353-61
pubmed: 23582715
J Proteome Res. 2017 Feb 3;16(2):384-392
pubmed: 28152591
J Proteome Res. 2020 Nov 6;19(11):4417-4427
pubmed: 32786691
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Front Immunol. 2021 Oct 28;12:738093
pubmed: 34777349
Lancet. 2003 Mar 8;361(9360):827-33
pubmed: 12642050
J Thromb Haemost. 2011 Jul;9 Suppl 1:182-8
pubmed: 21781254
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Crit Care Med. 2000 Apr;28(4 Suppl):N60-6
pubmed: 10807317
Lancet Child Adolesc Health. 2021 May;5(5):323-331
pubmed: 33711293
Sci Rep. 2020 Dec 29;10(1):22418
pubmed: 33376242
Animals (Basel). 2022 Feb 16;12(4):
pubmed: 35203200
Sci Rep. 2015 Dec 01;5:17632
pubmed: 26621497
Sci Rep. 2022 Aug 17;12(1):13922
pubmed: 35978025
Front Immunol. 2022 Jul 12;13:954121
pubmed: 35903092
Cell. 2022 Mar 3;185(5):916-938.e58
pubmed: 35216673
J Proteome Res. 2022 Apr 1;21(4):975-992
pubmed: 35143212
Comput Struct Biotechnol J. 2017 Jun 06;15:359-365
pubmed: 28660014
J Am Soc Nephrol. 2005 Oct;16(10):2920-30
pubmed: 16093453
Immunity. 2020 Nov 17;53(5):1108-1122.e5
pubmed: 33128875
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Front Immunol. 2014 Aug 21;5:402
pubmed: 25191325
PLoS One. 2011 Feb 08;6(2):e16945
pubmed: 21347455
Cell Metab. 2020 Oct 6;32(4):524-536
pubmed: 32853548
CJC Open. 2021 Aug;3(8):1060-1074
pubmed: 33875979
Sci Transl Med. 2020 Apr 15;12(539):
pubmed: 32295901